<i>TOLLIP</i> , <i>MUC5B</i> , and the Response to <i>N</i> -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
Justin M. Oldham(Michigan Medicine), Imre Noth(University of Virginia), Ganesh Raghu(University of Washington), Eleanor Valenzi(University of Pittsburgh), Yong Huang(Institute of Infection and Immunity), Cathryn Lee(University of Chicago), Shwu‐Fan Ma(University of Chicago), Mary E. Strek(University of Chicago), Kevin J. Anstrom(University of North Carolina at Chapel Hill), Leah J. Witt(University of Chicago), David A. Schwartz(Perinatal Institute), Fernando J. Martínez(University of Massachusetts Chan Medical School), Rekha Vij(University of Chicago)
American Journal of Respiratory and Critical Care Medicine
September 2, 2015
Cited by 358
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k